Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 24, Issue 3, Pages 281-290Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612824666180110102341
Keywords
Chronic inflammatory disease; atherosclerosis; cardiovascular disease; inflammation; rheumatoid arthritis; psoriasis; inflammatory bowel disease; periodontitis
Categories
Funding
- LEO Foundation
- Borregaard Clinical Scientist Fellowship from the Novo Nordisk Foundation
Ask authors/readers for more resources
Inflammation plays a significant role in atherosclerosis and cardiovascular disease (CVD). Patients with chronic inflammatory diseases are at increased risk of CVD, but it is debated whether this association is causal or dependent on shared risk factors, other exposures, genes, and/or inflammatory pathways. The current review summarizes epidemiological, clinical, and experimental data supporting the role of shared inflammatory mechanisms between atherosclerotic CVD and rheumatoid arthritis, psoriasis, inflammatory bowel disease, and periodontitis, respectively, and provides insights to future prospects in this area of research. Awareness of the role of inflammation in CVD in patients with chronic inflammatory diseases and the potential for anti-inflammatory therapy, e.g., with tumor necrosis factor-a inhibitors, to also reduce atherosclerotic CVD has evolved into guideline-based recommendations. These include regular CVD risk assessment, aggressive treatment of traditional CVD risk factors, and recognition of reduced CVD as an added benefit of strict inflammatory disease control. At present, chronic inflammatory diseases would appear to qualify as partners in crime and not merely innocent bystanders to CVD. However, definite incremental contributions of inflammation versus effects of the complex interplay with other CVD risk factors may never be fully elucidated and for the foreseeable future, inflammation is posed to maintain its current position as both a marker and a maker of CVD, with clinical utility both for identification of patient at risk of CVD and as target for therapy to reduce CVD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available